The impact of single dose intravenous dexamethasone as an adjunctive therapy for primary treatment on concentrations of inflammatory biomarkers in children with Kawasaki disease
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study was performed to investigate the impact of single dose dexamethasone as an adjunctive therapy for primary treatment on values of inflammatory markers in children with Kawasaki disease (KD). Methods: We investigated inflammatory markers, including white blood cells, erythrocyte sedimentation rate, C-reactive protein (CRP), interleukin (IL)-6, and IL-10 in 42 children with complete KD who were hospitalized in the Kyungpook National University Children’s Hospital from March 2016 through April 2017. The children underwent primary treatment for KD with intravenous immunoglobulin (IVIG) and/or dexamethasone. They were divided into 2 groups according to the use of dexamethasone. To assess the change in values of inflammatory markers, the blood was drawn twice from each child; before and 24 hours after the administration of IVIG. Results: Of the 42 study children, 18 and 24 were classified as the dexamethasone and control groups, respectively. No significant differences were found between the 2 groups in terms of the length of hospital stay, duration of fever, and time required for IVIG administration. In both groups, white blood cells, CRP, IL-6, and IL-10 significantly decreased after the primary therapy. The delta scores of CRP, IL-6, and IL-10 were higher in the dexamethasone group (P = 0.015, P = 0.001, and P = 0.002, respectively). No coronary artery abnormalities were found in both groups. Conclusion: This study suggests an anti-inflammatory effect of single dose dexamethasone as an adjunctive therapy for primary treatment in children with KD without shortening the duration of fever and the length of hospital stay.
Abstract
Purpose: This study was performed to investigate the impact of single dose dexamethasone as an adjunctive therapy for primary treatment on values of inflammatory markers in children with Kawasaki disease (KD). Methods: We investigated inflammatory markers, including white blood cells, erythrocyte sedimentation rate, C-reactive protein (CRP), interleukin (IL)-6, and IL-10 in 42 children with complete KD who were hospitalized in the Kyungpook National University Children’s Hospital from March 2016 through April 2017. The children underwent primary treatment for KD with intravenous immunoglobulin (IVIG) and/or dexamethasone. They were divided into 2 groups according to the use of dexamethasone. To assess the change in values of inflammatory markers, the blood was drawn twice from each child; before and 24 hours after the administration of IVIG. Results: Of the 42 study children, 18 and 24 were classified as the dexamethasone and control groups, respectively. No significant differences were found between the 2 groups in terms of the length of hospital stay, duration of fever, and time required for IVIG administration. In both groups, white blood cells, CRP, IL-6, and IL-10 significantly decreased after the primary therapy. The delta scores of CRP, IL-6, and IL-10 were higher in the dexamethasone group (P = 0.015, P = 0.001, and P = 0.002, respectively). No coronary artery abnormalities were found in both groups. Conclusion: This study suggests an anti-inflammatory effect of single dose dexamethasone as an adjunctive therapy for primary treatment in children with KD without shortening the duration of fever and the length of hospital stay.
참고문헌 (18)
- Yanagawa H, "Nationwide survey on Kawasaki disease in Japan", Pediatrics, 80, pp.58~62 (1987)
- Morens DM, "National surveillance of Kawasaki disease", Pediatrics, 65, pp.21~25 (1980)
- Kato H, "Myocardial infarction in Kawasaki disease : clinical analyses in 195 cases", J Pediatr, 108, pp.923~927 (1986)
- Suzuki A, "Coronary arterial lesions of Kawasaki disease : cardiac catheterization findings of 1100 cases", Pediatr Cardiol, 7, pp.3~9 (1986)
- McCrindle BW, "Diagnosis, treatment, and long-term management of Kawasaki disease : a scientific statement for health professionals from the American Heart Association", Circulation, 135, pp.e927~e929 (2017)
- Chen S, "Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease : a meta-analysis", Heart, 99, pp.76~82 (2013)
- Kobayashi T, "Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease(RAISE study) : a randomised, openlabel, blinded-endpoints trial", Lancet, 379, pp.1613~1620 (2012)
- Sinha A, "Pulse steroid therapy", Indian J Pediatr, 75, pp.1057~1066 (2008)
- Sophie Samuel, "Pharmacologic Characteristics of Corticosteroids", Journal of Neurocritical Care, 10(2), pp.53~59 (2017), 대한신경집중치료학회[DOI]
- Rigante D, "Critical overview of the risk scoring systems to predict non-responsiveness to intravenous immunoglobulin in Kawasaki syndrome", Int J Mol Sci, 17, pp.278~ (2016)
- Dallaire F, "New equations and a critical appraisal of coronary artery Z scores in healthy children", J Am Soc Echocardiogr, 24, pp.60~74 (2011)
- Sundel RP, "Corticosteroids in the initial treatment of Kawasaki disease : report of a randomized trial", J Pediatr, 142, pp.611~616 (2003)
- Okada Y, "Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children", J Pediatr, 143, pp.363~367 (2003)
- Kobayashi T, "Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease", Pediatr Infect Dis J, 28, pp.498~502 (2009)
- Kim MJ, "Corticosteroid therapy for children in pediatric emergency department", Pediatr Emerg Med J, 2, pp.16~21 (2015)
- Makata H, "Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro : implication for treatment of Kawasaki disease", Naunyn Schmiedebergs Arch Pharmacol, 373, pp.325~332 (2006)
- Jibiki T, "Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease", Eur J Pediatr, 163, pp.229~233 (2004)
- 임윤주, "Clinical Outcomes of Initial Dexamethasone Treatment Combined with a Single High Dose of Intravenous Immunoglobulin for Primary Treatment of Kawasaki Disease", Yonsei Medical Journal, 55(5), pp.1260~1266 (2014), 연세대학교의과대학[DOI]